

CURRICULUM VITAE

Carol McMillen Moinpour, Ph. D.

Current Address: Southwest Oncology Group
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N., M3-C102
Seattle, Washington 98109-1024

Phone: Office: (206) 667-4604

Education: Ohio State University, B.S., (Education), 1963
Ohio State University, M.A., (Psychology), 1965
University of Washington, Ph.D., (Psychology), 1973

Professional Positions:

Affiliate Professor, Department of Health Services, School of Public Health & Community Medicine, University of Washington, July 2009-present.

Member, Division of Public Health Sciences [Cancer Prevention Program/Southwest Oncology Group Statistical Center], Fred Hutchinson Cancer Research Center, July 2008-present.

Behavioral Scientist, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, September 1993-July 2010.

Affiliate Associate Professor, Department of Health Services, School of Public Health & Community Medicine, University of Washington, July 1999-2009.

Associate Member, Division of Public Health Sciences [Biostatistics Program/Southwest Oncology Group], Fred Hutchinson Cancer Research Center, January 1999-July 2008.

Assistant Member, Division of Public Health Sciences [Cancer Prevention Research Program/Biostatistics Program], Fred Hutchinson Cancer Research Center, October 1993-December 1998.

Affiliate Assistant Professor, Department of Health Services, School of Public Health & Community Medicine, University of Washington, November 1993-June 1999.

Associate in Public Health Sciences, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center. January 1993-September 1993.

Staff Scientist and Consultant, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center. 1987-1992.

Psychologist, Early Discharge Trial. Fred Hutchinson Cancer Research Center, Seattle, WA, May, 1989-1992.

Investigator, Child/Adolescent Biosocial Study, Pain and Toxicity Research Program Project. Fred Hutchinson Cancer Research Center, Seattle, Washington, 1987-1992.

Staff Scientist, Hospice Study. Fred Hutchinson Cancer Research Center, Seattle, Washington, 1987-1988.

National Research Service Award Fellow, Alcohol, Drug Abuse, and Mental Health Administration, DHHS. Department of Biostatistics, University of Washington, 1984-1987.

Project Director, Evaluation of Cancer Management Study. NIH, Bureau of Manpower, Division of Nursing, 1983-1984.

Project CHOICE. Cancer Prevention Family Curriculum. Fred Hutchinson Cancer Research Center, Seattle, Washington, 1982-1983.

Associate Director, Action Alliance. Washington State (Administration for Children, Youth and Families, DHHS), 1980-1982.

Social Science Analyst, Division of Prevention, Office of the Administrator, Alcohol, Drug Abuse, and Mental Health Administration, DHHS 1979-1980.

Consultant, DHEW Expert, office of the Assistant Secretary for Planning and Evaluation, Day Care Division, DHEW. 1976-1979.

Member of the faculty, Evergreen State College, Olympia, Washington, 1972-1976.

Publications:

Journals:

1. Smith A, Spence (Moinpour) CM. National day care study: Optimizing the day care environment. *Am J Orthopsychiatry* 50(4):718-721, 1980.
2. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Jr., Crowley J. Quality of life end points in cancer clinical trials: Review and recommendations. *J Natl Cancer Inst* 81(7):485-494, 1989.
3. McCorkle R, Benoliel JQ, Donaldson G, Georgiadou F, Moinpour CM, Goodell B. A randomized clinical trial of home nursing care for lung cancer patients. *Cancer* 64(6):1375-1382, 1989.
4. Moinpour CM, Polissar L. Factors affecting place of death of hospice and non-hospice cancer patients. *Am J Public Health* 79(11):1549-1551, 1989.
5. Moinpour CM, Polissar L, Conrad D. Factors associated with length of stay in hospice. *Med Care* 28(4):363-368, 1990.
6. Donaldson G, Moinpour CM. Strengthened estimates of individual pain trends in children following bone marrow transplantation. *Pain* 48(2):147-155, 1992.
7. Nayfield SG, Ganz P, Moinpour CM, Cella DF, Hailey BJ. Report from a National Cancer Institute workshop on quality of life assessment in cancer clinical trials. *Quality of Life Research* 1(3):203-210, 1992.
8. Hayden KA, Moinpour CM, Metch B, Feigl P, O'Bryan RM, Green S, Osborne CK. Pitfalls in quality of life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial. *Oncol Nurs Forum* 20(9):1415-1419, 1993.
9. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): Position paper from the World Health Organization. *Soc Sci Med* 41(10):1403-1409, 1995.
10. Moinpour CM. Costs of quality of life research in Southwest Oncology Group trials. *J Natl Cancer Inst Monogr* 20:11-16, 1996.
11. Loll, LC, Moinpour CM, Feigl P. Southwest Oncology Group (SWOG). [A cooperative group report on quality of life research: Lessons learned] *J. Natl Cancer Inst Monogr* 20:8385, 1996.
12. Moinpour CM, Lovato LC. Ensuring the quality of quality of life data: The Southwest Oncology Group experience. *Stat Med* 17(5/6/7):641-651, 1998.
13. Bernhard J, Cella DP, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, Mosconi P, Osoba D, Simes J, Hurny C. Missing quality of life data in cancer clinical trials: Serious problems and challenges. *Stat Med* 17(5/6/7):517-532, 1998.
14. Brown ML, Glick HA, Harrell FE, Herndon JE, McCabe MS, Moinpour C, Schulman K, Smith TJ, Weeks JC, Seils DM. Integrating economic analysis into cancer clinical trials: The National Cancer Institute-American Society of Clinical Oncology Economics Workbook. *J Natl Cancer Inst Monogr* 24:1-28, 1998.
15. Geyer CE, Jr., Green SJ, Moinpour C, O'Sullivan J, Goodwin D, Canfield V, Meyers F, Martino S. Expanded Phase II trial of Paclitaxel as 3 hour infusion in women with refractory metastatic breast cancer. Evaluating symptom reduction, objective response, and toxicity: A Southwest Oncology Group (SWOG) study. *Breast Cancer Res Treat* 51:169-181, 1998.
16. Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, Higgins B, Skeel R, Yee M, Meyskens FL Jr. Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial. *J Natl Cancer Inst* 90:1537-1544, 1998.
17. Holcombe RF, Jacobsen J, Ailing L, Moinpour CM. Inclusion of African Americans in oncology clinical trials: The LSU Medical Center Experience. *Am J Clin Oncol* 22:18-21, 1999.
18. Donaldson GW, Moinpour CM, Bush NE, Chapko M, Jocom J, Siadak M, Nielsen-Stoeck M, Bradshaw JM, Bichindaritz I, Sullivan KM. Physician participation in research surveys: a randomized study of inducements to return mailed research questionnaires. *Eval Health Prof* 22:427-441, 1999.
19. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM. Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. *Qual Life Res* 8:723-731, 1999.

20. Ramsey SD, Andersen MR, Moinpour CM, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal cancer. *Cancer* 88:1294-1303, 2000.
21. Moinpour CM, Lovato LC, Thompson, IM Jr., Ware JE, Jr., Ganz PA, Patrick DL, Shumaker SA, Donaldson GW, Ryan A, Coltman CA Jr. Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. *J Clin Oncol* 18(9):1942-1953, 2000.
22. Moinpour CM, Triplett JS, McKnight B, Upchurch C, Lovato LC, Leichman CG, Muggia FM, Tanaka L, James WA, Lennard M, Meyskens FL Jr. Challenges posed by nonrandom missing quality of life data in an advanced-stage colorectal cancer clinical trial. *Psycho-Oncology* 9:340-354, 2000.
23. Moinpour CM, Lyons B, Schmidt SP, Chansky K, Patchell RA. Substituting proxy ratings for patient ratings in cancer clinical trials: An analysis based on a Southwest Oncology Group trial in patients with brain metastases. *Qual Life Res* 9:219-231, 2000.
24. Stern JM, Bruemmer B, Moinpour CM, Sullivan KM, Lenssen P, Aker SN. Impact of a randomized controlled trial of liberal versus conservative discharge criteria on calorie, protein and fluid intake in marrow transplant patients. *J Amer Dietetic Assoc* 100:1015-1022, 2000.
25. Gotay C, Moinpour CM, Moody Thomas S, Gritz ER, Albain KS, DeAntoni E, Hansen L, Ganz PA. Behavioral science research in the cooperative group setting: The experience of the Southwest Oncology Group. *J Natl Cancer Inst* 92(17):1381-1387, 2000.
26. Moinpour CM, Atkinson JO, Thomas SM, Underwood SM, Harvey CH, Parzuchowski J, Lovato L, Ryan A, Hill S, DeAntoni E, Gritz ER, Thompson IM, Coltman CA Jr. Minority recruitment in the Prostate Cancer Prevention Trial. *Ann Epidemiol* 10(8 supplement 1):S85-S91, 2000.
27. Kiebert G, Wait S, Bernhard J, Bezjak A, Cella D, Day R, Houghton J, Moinpour CM, Scott C, Stephens R. Practice and policy of measuring quality of life and health economics in cancer clinical trials: A survey among co-operative trial groups. *Qual Life Res* 9:1073-1080, 2000.
28. Thompson IM, Tangen CM, Tolcher A, Crawford ED, Eisenberger M, Moinpour CM. Association of African American ethnic background with survival in men with metastatic prostate cancer. *J Natl Cancer Inst* 93:219-225, 2001.
29. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain M, Sartor AO, Chatta GS, Lowe BA, Eisenberger M, Crawford ED. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG-9235). *Urology* 58:53-58, 2001.
30. Kelly K, Crowley J, Bunn Jr. PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. *J Clin Oncol* 19(13):3210-3218, 2001.
31. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, and Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. *J Natl Cancer Inst* 94(4):291-297, 2002.
32. Moinpour CM, Lyons B, Grevstad P, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial. *Quality of Life Research* 11(2):115-126, 2002.
33. Donaldson GW, Moinpour CM. Individual differences in quality-of-life treatment response. *Med Care* 40(6 Suppl):III-39—III-53, 2002.
34. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. *Am J Gastroenterol* 97(5):1228-1234, 2002.
35. Sprangers MAG, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA, The Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a user's guide for clinicians. *Mayo Clin Proc* 77(6):561-571, 2002.
36. Pauler DK, McCoy S, Moinpour C. Pattern mixture models for longitudinal quality of life studies in advanced stage disease. *Stat Med* 22:795-809, 2003.
37. Hannon PA, Bowen DJ, Moinpour CM, McLerran DF. Correlations in perceived food use between the family food preparer and their spouses and children. *Appetite* 40:77-83, 2003.
38. Trentham-Dietz A, Remington PL, Moinpour CM, Hampton JM, Sapp AL, Newcomb PA. Health-related quality of life in female long-term colorectal cancer survivors. *Oncologist* 8(4):342-349, 2003.
39. Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI. Health status and quality of life in patients with early-stage

- Hodgkin's disease treated on Southwest Oncology Group study 9133. *J Clin Oncol* 21(18):3512-3519, 2003.
40. Sapp AL, Trentham-Dietz A, Newcomb PA, Hampton JM, Moinpour CM, Remington PL. Social networks and quality of life among female long-term colorectal cancer survivors. *Cancer* 98(8):1749-1758, 2003.
 41. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 351(15):1513-1520, 2004.
 42. Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 95:506-512, 2004.
 43. Hansen LK, Feigl P, Modiano MR, Lopez JA, Sluder SE, Moinpour CM, Pauler DK, Meyskens FL. An educational program to increase cervical and breast cancer screening in Hispanic women. *Cancer Nurs* 28(1):47-53, 2005.
 44. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson Jr IM, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, et al. Designing the Selenium and Vitamin E cancer prevention trial (SELECT). *J Natl Cancer Inst* 97(2):94-102, 2005.
 45. Bush N, Donaldson G, Moinpour C, Haberman M, Milliken D, Markle V, Lauson J. Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. *Qual Life Res* 14:77-93, 2005.
 46. Eton DT, Lai J-S, Cella D, Reeve BB, Talcott JA, Clark JA, McPherson CP, Litwin MS, Moinpour CM. Data pooling and analysis to build a preliminary item bank--an example using bowel function in prostate cancer. *Eval Health Prof* 28(2):142-159, 2005.
 47. Hollen PJ, Gralla RJ, Kris MG, McCoy S, Donaldson GW, Moinpour CM. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life? *Qual Life Res* 14:837-847, 2005.
 48. Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. *Am J Clin Oncol* 28(1):17-20, 2005.
 49. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. *JAMA* 294(23):2996-3002, 2005.
 50. Berry DL, Moinpour CM, Jiang CS, Ankerst D Pauler, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MHA, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. *J Clin Oncol* 24(18):2828-2835, 2006.
 51. Hesketh PJ, Chansky K, Lau DHM, Doroshov JH, Moinpour CM, Chapman RA, Goodwin W, Gross HM, Crowley JJ, Gandara DR. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). *J Thorac Oncol* 1(6):537-544, 2006.
 52. Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. *Support Care Cancer* 14:988-998, 2006.
 53. Gotay CC, Moinpour CM, Unger JM, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil S, Gross HM, Lippman S, Albain KS. Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. *J Clin Oncol* 25(15):2093-2099, 2007. PMID: 17513815.
 54. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Jr, Langley C, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention trial. *J Natl Cancer Inst* 99(13):1025-1035, 2007. PMID: 17596576.
 55. Moinpour CM, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data? *J Natl Cancer Inst Monogr* 37:31-38, 2007. PMID: 17951229.
 56. Moinpour CM, Denicoff AM, Bruner DW, Kornblith AB, Land SR, O'Mara A, Trimble E. Funding patient-reported outcomes in cancer clinical trials. *J Clin Oncol* 25(23):5100-5105, 2007.
 57. Bowen DJ, Fann JR, Andersen MR, Rhew IC, Gralow JR, Lewis FM, Hunt JR, Palomares M, Moinpour CM, Ankerst DP. Recruiting patients with breast cancer and their families to behavioral research in the post-HIPAA period. *Oncol Nurs Forum* 34(5):1049-1054, 2007. PMID: 17878132.

58. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Jr, Redman MW, Canby-Higano ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol* 26(1):112-120, 2008. PMID: 18165645.
59. Ganz PA, Hussey MA, Moinpour CM, Unger JM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. *J Clin Oncol* 26(8):1223-1230, 2008. PMID: 18227530.
60. Goodwin JW, Green SJ, Moinpour CM, Bearden JD, III, Giguere JK, Jiang CS, Lippman SM, Martino S, Albain KS. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group study 9626. *J Clin Oncol* 26(10):1650-1656, 2008. PMID: 18375894.
61. Donaldson GW, Nakamura Y, Moinpour C. Mediators, moderators, and modulators of causal effects in clinical trials--dynamically modified outcomes (DYNAMO) in health-related quality of life. *Qual Life Res* 18:137-145, 2009. PMID: 19152118
62. Moinpour CM, Donaldson GW, Nakamura Y. Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: dynamically modified outcomes (DYNAMO) analysis of a randomized controlled trial. *Qual Life Res* 18:147-155, 2009. PMID: PMC2859212.
63. Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. *Am J Manag Care* 16(5):e121-e130, 2010. PMID: 20455638
64. Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study of gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. *J Clin Oncol* 28(22):3611-3616, 2010. PMID: 20606094, PMID: PMC2917316
65. Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, et al. Patient preferences and urologist recommendations among local stage prostate cancer patients who present for initial consultation and second opinions. *World J Urol.*, E-pub ahead of print, October, 2010. PMID: 20959991.

In Press:

Submitted Manuscripts:

1. Dolan E, McGregor B, Bowen D, Moinpour C. Coping behaviors mediate the effects of optimism on health status and quality of life in a community sample of women. Submitted, *Health Psychology*, 2010.
2. Zeliadt S, Penson D, Moinpour C, et al. Provider and partner interactions in the treatment decision making process for newly diagnosed localized prostate cancer. Submitted *BJU Int*, July 2010.
3. Brell JM, Hershman D, Moinpour C, et al. Chemotherapy induced peripheral neuropathy: report of an NCI clinical trials planning meeting. Submitted, *J Natl Cancer Inst*, August 2010.

Invited Discussions:

1. Moinpour CM, Feigl P, Metch B, Hayden KA, et al. Response. *J Natl Cancer Inst* 81(14):1106-1107, 1989.
2. Ganz PA, Moinpour CM, Cella DF, Fetting JH. Invited commentary. Quality of life assessment in cancer clinical trials. A status report. *J Natl Cancer Inst* 84(13):994-995, 1992.
3. Moinpour CM. The Gotay et al article reviewed. *Oncol* 6(6):32 and 37, 1992.
4. Moinpour CM. Invited Commentary. The Skeel Article Reviewed. *Oncol* 7(12):65-66, 1993.

5. Moinpour CM. Invited Discussion: Do quality of life assessments make a difference in the evaluation of cancer treatments? *Control Clin Trials* 18:311-317, 1997.
6. Moinpour CM, Troxel A, Lovato LC, Eisenberger M, Blumenstein BA, Crawford ED. Response. *J Natl Cancer Inst* 91:381-382, 1999.
7. Moinpour CM, Troxel A, Lovato LC, Eisenberger M, Blumenstein BA, Crawford ED. Response: *J Natl Cancer Inst* 91:646, 1999.
8. Moinpour CM, Thompson Jr. IM. The Kim et al. Article reviewed. *Oncol* 13:835-836, 1999.
9. Moinpour CM, Ganz PA, Rowland JH, Gritz ER, Gotay CC. Guest Editorial: The value of quality of life data in judging patient benefit. *Cancer Letter* 25(33):1-5, 1999.
10. Donaldson GW, Moinpour CM. Learning to live with missing quality-of-life data in advanced-stage disease trials. *J Clin Oncol* 23(30):7380-7384, 2005.

Book Chapters, Proceedings:

1. McCorkle R, Moinpour CM, Saunders J. The impact of advanced disease on functional status. *Proceedings of the 14th International Union Against Cancer, Budapest, Hungary, 1986.*
2. Moinpour CM, McCorkle R, Saunders J. Measuring functional status. In: M Frank-Stromberg (ed), *Instruments for Clinical Nursing Research*. Pittsburgh, PA: Oncology Nursing Society, 23-45, 1988.
3. Moinpour CM, Donaldson G, Wallace K, Hiraga Y, Joss B. Parent/child agreement in rating child mouth pain. In: DC Tyler and EJ Krane (eds.), *Advances in Pain Research and Therapy*. Vol. 15. *Pediatric Pain*. New York, Raven Press, 69-78, 1990.
4. Moinpour CM, Hayden K, Thompson I, Feigl P, Metch B. Quality of life measurement in Southwest Oncology Group trials: Policies and implementation. In: NS Tchekmedyian and DF Cella (eds.), *Quality of life in oncology practice and research*. Williston Park, NY: Dominus Publishing Co., pp. 43-49, 1991.
5. Moinpour CM, Chapman CR. Pain management and quality of life. In: KA Lehmann, D Zech (eds), *Transdermal Fentanyl. A New Approach to Pain Control*. Berlin, Springer-Verlag, 1991.
6. Moinpour CM, Georgiadou F, Donaldson G, Chapman CR. Cancer pain and quality of life. In: CR Chapman and K Foley (eds), *Current and Emerging Issues in Cancer Pain: Research and Practice*. New York: Raven Press, 267-282, 1993.
7. Moinpour CM. Measuring quality of life: An emerging science. In: *Proceedings of the Navelbine investigators meeting. The current status of Navelbine (Vinorelbine) in the treatment of advanced non-small cell lung cancer*. *Semin Oncol* 21(5)(Suppl):48-63, 1994.
8. Moinpour CM. Quality of life assessment in Southwest Oncology Group clinical trials: Translating and validating a Spanish questionnaire. In: *Quality of life assessment in health care settings*. WHO/IPSEN Foundation Series. Berlin: Springer-Verlag, 83-97, 1994.
9. Moinpour CM, Chapko MK, Sullivan KM, Kirk S. Charges associated with traditional inpatient and outpatient care for marrow transplant patients. In: PC Buchsel (ed), *Bone marrow transplant: Administrative strategies and clinical issues*. Boston: Jones & Barlett, 427-441, 1995.
10. Moinpour CM, Savage M, Hayden KA, Sawyers J, Upchurch C. Quality of life issues in cancer. In: J E. Dimsdale, A Baum (eds), *Perspectives on behavioral medicine*. Hillsdale, NJ: Lawrence Erlbaum Assoc., 79-95, 1995.
11. Gralla RJ, Moinpour CM. Assessing quality of life in patients with lung cancer. A guide for clinicians. *Proceedings of the Lung Cancer Quality of Life Symposium/7th World Conference on Lung Cancer, Bolder, Colorado, June 26-27, 1994*. New York: NCM Publishers, Inc., 1995.
12. Bichindaritz E, Siadak MF, Jocom J, Moinpour C, Kansu E, Donaldson G, Bush N, Chapko M, Bradshaw JM, Sullivan KM. CARE-PARTNER: a computerized knowledge-support system for stem-cell post-transplant long-term follow-up on the World-Wide-Web. *American Medical Informatics Association (AMIA), Annual Symposium; Orlando, FL, 1998*, 386-390.
13. Troxel A, Moinpour CM. Statistical analysis of quality of life. In: J Crowley (ed.), *Handbook of Statistics in Clinical Oncology*. New York: Marcel Dekker, 2001.
14. Moinpour CM, Provenzale, D. Treatment for colorectal cancer: Impact on health-related quality of life. In: J Lipscomb, CC Gotay, C Snyder, *Outcomes Assessment in Cancer: Findings and Recommendations of the Cancer Outcomes Measurement Working Group, Chapter 7*. New York: Cambridge University Press 2005.

15. Troxel A, Moinpour CM. Design and analysis of quality of life data. In: J Crowley and DP Ankerst (eds.), *Handbook of Statistics in Clinical Oncology: Second Edition, Revised and Expanded*. Boca Raton, FL: Dekker, 2006.
16. Bowen DJ, Moinpour CM, Andersen MR, Meischeke H, Thompson B, Cochrane B. Creating a theoretical framework for public intervention design. The Social Sciences Research Group, Fred Hutchinson Cancer Research Center. In: S Miller, DJ Bowen, RT Croyle, J Rowland (eds.), *Handbook of behavioral science and cancer*. Washington, DC: American Psychological Association (in press).

Abstracts/Oral Presentations/Invited Talks:

1. Donaldson G, Moinpour CM. Credibility of self-report and parent report of oral mucositis pain during bone marrow transplantation (BMT) in children. *Pain* 5(Suppl):S30, 1990.
2. Sullivan KM, Moinpour CM, Chapko MK, Buchsel P, Appelbaum FR, Buckner CD, Hansen J, Storb R. Reducing the costs of blood and marrow transplantation: A randomized study of early hospital discharge and the results of revised standard practice guidelines. *Blood* 84(10):250a, 1994.
3. Berry DL, Moinpour C, Blumenstein BA, Thrasher B, Ellis WJ. Measurement of irritative bladder symptoms. *Oncol Nurs Forum Congress* 24:319, 1996.
4. Geyer CE Jr., Green SJ, Moinpour C, O'Sullivan J, Goodwin D, Canfield V, Hamaski V, Martino S. A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: A Southwest Oncology Group (SWOG) study. *Proc ASCO* 15:107, 1996.
5. Kucuk O, Blumenstein B, Moinpour C, Lew D, Coleman D, Eisenberg M, Crawford D. Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: A Southwest Oncology Group (SWOG) study. *Proc ASCO* 15:245, 1996.
6. Moinpour CM, Ferrans C. Quality of Life Assessment in Cancer Clinical Trials. One Day Workshop for Division of Cancer Prevention and Control/NCI Project Staff, April 1997.
7. Moinpour CM, Savage M, Lovato L, Troxel A, Skeel R, Eisenberger MA, Crawford ED, Meyskens FL, Jr. Quality of life (QOL) endpoints in advanced stage prostate cancer: A randomized, double blind study comparing flutamide to placebo in orchiectomized stage D2 prostate patients (pts). *Proc ASCO* 16:53a, 1997.
8. Moinpour CM, Lovato LL, Schmidt CS. Prostate Cancer Prevention Trial: Baseline Quality of Life and Demographic Profile. Paper presented at the Medical Outcomes Trust Annual Meeting, San Francisco, CA, May, 1997.
9. Moinpour CM, Lovato LC, Ware JE Jr., Ryan, Thompson IM, Coltman CE Jr. A chemoprevention trial to prevent prostate cancer: Profile of participants. Paper presented at the American Psychological Association Meetings (Division 34: Population and Environmental Psychology), Chicago, August, 1997.
10. Moinpour C, Donaldson G, Padilla G, Ganz P, Lovato L, Piñeros S. English and Spanish versions of the Southwest Oncology Group (SWOG) Quality of Life (QOL) Questionnaire: Validation of a total score. Oral presentation. *Qual Life Res* 7(7):638, 1998.
11. Moinpour C. Evaluation and quality of life. Invited Speaker, Future Trends in Prostate Cancer. Hamilton Regional Cancer Centre, Hamilton, Ontario, Nov. 18, 1998.
12. Moinpour CM, Lyons B, Schmidt SP, Patchell RA. Patient/proxy agreement for the Spitzer QL-Index in a Southwest Oncology Group trial for patients with brain metastases. Oral presentation. *Qual Life Res* 8(7):581, 1999.
13. Ramsey SD, Moinpour CM, Lovato LC, Grevstad PK, Kelly K, Presant C. An economic analysis of Southwest Oncology Group Trial S9509: Cisplatin/vinorelbine vs. Carboplatin/paclitaxel for advanced non-small cell lung cancer. *Proc ASCO* 19:489a, 2000. (Poster Discussion Session)
14. Moinpour CM, Lyons B, Lovato LC, Grevstad P, Kelly K, Crowley JJ, Gandara D. Comparison of quality of life (QOL) outcomes for two chemotherapy regimens in non-small cell lung cancer (NSCLC). Oral Session to be presented at the 9th World Conference on Lung Cancer, Tokyo, Japan, September 11-15, 2000.
15. Ramsey SD, Moinpour CM, Lovato LC, Grevstad PK, Presant C, Gandara D, Kelly K. An economic analysis alongside a prospective randomized multicenter clinical trial of cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non-small cell lung cancer. Oral Session to be presented at the 9th World Conference on Lung Cancer, Tokyo, Japan, September 11-5, 2000.

16. Moinpour CM. Using Health-related quality of life (HRQL) instruments in cancer care: The impact of individual differences. Seattle Symposium on Cancer Outcomes Research, September 22-23, 2000, Seattle, WA.
17. Moinpour CM, Donaldson GW, Padilla GV, Ganz PA, Pineros SL, Lovato LC. Health-related quality of life (HRQL) correlates of perceived overall health in Spanish-and-English-speaking breast cancer populations. Oral presentation. *Qual Life Res* 9(3):250, 2000.
18. Ryan AM, Goodman P, Hill S, Moinpour CM. Promoting adherence to the Prostate Cancer Prevention Trial end-of-study biopsy requirement. *Control Clin Trials* 22:2S, 2001.
19. Moinpour CM. Using structural equation modeling to test measurement equivalence of English and Spanish questionnaires. Oral presentation, International Society for Quality of Life Research meeting, November 7-10, 2001, Amsterdam, The Netherlands.
20. Bush NE, Donaldson GW, Moinpour, CM. Quality-of-life measures as leading indicators of adverse clinical events after bone marrow and stem cell transplantation. *Clin Ther* 24(Supp B):9-11, 2002.
21. Bush NE, Donaldson GW, Moinpour CM. Quality of life (QOL) as an early predictor of relapse and death after bone marrow and stem cell transplantation (BMT). *Qual Life Res* 11(7):649, 2002.
22. Moinpour CM, Lyons B, McCoy S, Winakur GL, Liu PY, Rothenberg ML. HRQL outcomes in a Phase II trial for patients with recurrent ovarian cancer: Was palliation achieved? *Qual Life Res* 11(7):660, 2002.
23. Sloan JA, Moinpour C, Berzon R, Bullinger M, Barofsky I, Wu AW. The costs of incorporating quality-of-life assessments into clinical practice and research: what resources are required? *Clin Ther* 25(Supp 4):D9, 2003.
24. Bush N, Moinpour C, Donaldson G, Haberman MR. Feasibility of very frequent web-based QOL home self-assessment after HSCT. *Qual Life Res* 12(7):780, 2003.
25. Moinpour C, Darke AK, Pauler DK, et al. Determining predictors of men's report of sexual problems: advantages of a two-part model for zero scores. *Qual Life Res* 12(7):748, 2003.
26. Moinpour C, Wu J, Donaldson G, Liepa A, Melemed A, O'Shaughnessy J, Rappold E, Albain K. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QOL) and pain palliation results from the global phase III study. *J Clin Oncol* 22:32, 2004 (suppl; abstr 621).
27. Berry DL, Moinpour CM, Jiang C, Vinson LV, Lara PN, Lanier S, Taplin ME, Burch PA, Petrylak DP, Crawford ED. Quality of life (QOL) and pain in advanced stage prostate cancer: Impact of missing data on evaluating palliation in SWOG 9916. *J Clin Oncol* 22:400, 2004 (suppl; abstr 4579).
28. Ganz PA, Moinpour CM, McCoy, S, Pauler DK, Press OW, Fisher RI. Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133. *J Clin Oncol* 22:567, 2004 (suppl: abstr 6546).
29. Moinpour CM, Donaldson GW, McCoy S, Hollen PJ, Gralla RJ, Dris MG. Agreement of health-related quality of life (HRQL) data obtained by different formats: Determining when substitution is appropriate. *Qual Life Res* 13:1525, 2004 (abstr 1610).
30. CC Gotay, CM Moinpour, C Jiang, DP Ankerst, D Coleman, S Martino, B Taylor, J Bearden, S Dakhil, H Gross, KS Albain. Enhancing Well-being during breast cancer recurrence: Preliminary findings from a phase III study. Poster presentation, Charles A Coltman, Jr. San Antonio Breast Cancer Symposium, *Breast Cancer Res Treat* 88 (Suppl 1): S140 (abstr 3080), 2004.
31. Hayden KA, Moinpour CM, Faulkner J, Tangen CM, Canby-Hagino ED, Lemmon D, Breslin S, Thompson IM, Crawford ED. Short- and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) trial. *J Clin Oncol* 23:391s (Abstract # 4556), 2005
32. Moinpour CM, Darke AK, Donaldson GW, Patrick DL, Ware JE Jr., Shumaker SA, Ganz PA, Thompson IM Jr. Modeling change in sexual function for men enrolled on the Prostate Cancer Prevention Trial (PCPT). *Qual Life Res* 14:2010 (Abstract #-5-B02/1504), 2005.
33. Invited speaker, "Assessing Patient-Reported Outcomes in Prevention Trials", Session: Challenges to the Dissemination of Results from Cancer Prevention Trials (PA Ganz, Chair), American Association for Cancer Research Frontiers in Cancer Prevention Research Meeting, November 15, 2006, Boston, MA.
34. Invited speaker for Session, "Identifying, Preventing and Ameliorating Late Effects in Cancer Survivors", Lisa Diller (Moderator), American Association for Cancer Research Meetings, Los Angeles, CA, April 14-18, 2007.

35. Moinpour CM, Donaldson GW, Liepa AM, Melemed AS, O'Shaughnessy J, Albain KS. Cumulative probability plots: a visual summary of patient benefit due to therapy. *Qual Life Res Suppl:A-9* (Abstr 1583), 2007.
36. Zeliadt SB, Hall IJ, Lee JW, Ekwueme DU, Penson DF, Ramsey SD, Moinpour CM. What choices do men feel they have in selection of prostate cancer treatment? [Patient, family member, and physician preliminary results] *Qual Life Res Suppl:A-69* (Abstr 1584), 2007.
37. Ramsey SD, Zeliadt SB, Hall IJ, Lee JW, Ekwueme DU, Moinpour CM, Penson DF. What choices do men feel they have in selection of prostate cancer treatment? [Preliminary results for low versus high risk patients] *International Society for Pharmacoeconomics and Outcomes Research. 10th Annual European Congress, Dublin, Ireland, October 20-23, 2007.*

Funded Research:

1. Principal Investigator, "Spanish Translation and Validation of the SWOG Quality of Life Questionnaire", (CA61674). (DCPC RFA: CA/NR-92-27 Quality of Life Assessment in Special Populations), 9/30/93 - 9/29/96.
2. Principal Investigator, Research Supplement for Underrepresented Minorities to CA61674, 9/30/94-9/29/96.
3. Consultant (Non-funded), "Prostate Cancer Practice Patterns and Health-Related Quality of Life", SEER contract, Janet Stanford, PhD, Principal Investigator, 1994-1997.
4. Consultant (Non-funded), "The Effects of Earlier Diagnosis of Colon Cancer on Treatment Costs and Quality of Life", Multiple SEER Contracts, Principal Investigators: Nicole Urban, Scott Ramsey 1994-1999.
5. Consultant (Funded), "Measurement of Irritative Bladder Symptoms", Donna Berry, Principal Investigator, Oncology Nursing Foundation Grant, 1995-1996.
6. Consultant (Non-funded), "Quality of Life of Adult Medium-term Survivors of Bone Marrow Transplantation", Gary Donaldson, Nigel E. Bush, Co-Investigators, 4/1/96-3/31/00.
7. Investigator (10%FTE), "Computerized Decision Support for Posttransplant Care", Fred Hutchinson Cancer Research Center, Keith M. Sullivan, Principal Investigator. Agency for Health Care Policy and Research, 9/1/96 - 8/31/99
8. Principal Investigator, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center Subcontract, "Enhancing Well-being During Breast Cancer Recurrence", Principal Investigators: Charles A. Coltman, Jr., Carolyn Gotay, Department of Defense Breast Cancer Research Program [top 5% of submitted proposals, designated "Gold Standard" proposal], 10/1/96-6/1/05.
9. Statistical Center Consultant (2.5% FTE/no salary), "Late Cardiac Effects of Survivors on SWOG-8897", Supplement through NCI RFA (5/97) to fund MUGA scans and patients identification and recruitment (Moinpour) for previously funded project, Principal Investigators: Charles A. Coltman, Jr., Patricia A Ganz., 10/97-9/98.
10. Consultant (Non-funded), "Decision-making by Men with Localized Prostate Cancer", First Award, Donna Berry, 4/1/98-3/31-03.
11. Consultant (Funded), "Well-being in Long-term Multiethnic Prostate Cancer Survivors", Carolyn Gotay, Principal Investigator, Funded through NCI Long-term Survivors RFA, 8/1/98-5/31/03.
12. Investigator (10%FTE), "Dynamic Quality of Life After Hematopoietic Transplant", Gary Donaldson, Principal Investigator., National Cancer Institute, Competing Renewal: 2/1/01-1/31/05.
13. Investigator (Co-Morbidity Study) (2.5% FTE), "Pharmacology of Anticancer Drugs in Advanced Age", Derek Ragahavan, Principal Investigator, National Cancer Institute, 10/1/00-9/30/03.
14. Consultant (funded), "QOL Stem Banking and Adaptive Testing in Prostate Cancer", David Cella, Principal Investigator, American Cancer Society, 7/1/01-present.
15. Consultant (funded) "Breast Carcinoma In Situ: Quality of Life and Recurrences. Polly A. Newcomb, Principal Investigator (University of Wisconsin), National Cancer Institute, 10/1/01-9/30/06.
16. Co-Investigator (4% FTE), "Long-term Quality of Life of Prostate Cancer Survivors", David Penson, Principal Investigator, National Cancer Institute, 7/2/04-6/30/07.
17. Principal Investigator, Pilot study funding from FHCRC of \$5000 6/1/03 to document men's compliance with the proposed exercise intervention for the R01 (1 R01 CA101929-01) re-submission.

The three-month pilot study was conducted at the University of Texas Health Sciences Center at San Antonio, one of the two proposed sites for the revised application.

18. Investigator (3%), “Localized Prostate Cancer: Decision Making and Outcomes”, S Ramsey, Principal Investigator, Centers for Disease Control, 9/30/04-9/29/07.
19. Principal Investigator, Pilot study funding from FHCRC of \$15,000 (2/05 - 6/06) to document exercise compliance for men with prostate cancer recruited from Virginia Mason Medical Center-Seattle. The bid & proposal request funds patient recruitment at Virginia Mason and a 3-month exercise program at the FHCRC Exercise Research Center.
20. Principal Investigator (5%), FHCRC Subcontract, “Biobehavioral Cancer Prevention & Control Training Program”, Donald Patrick, P.I., National Cancer Institute, 7/1/06-6/30/2011.
21. Investigator (5%), FHCRC Subcontract, University of Washington Submission “Assessment of Mood, Cognition and Quality of Life in ADT”, Monique Cherrier, Principal Investigator, R01 CA101929-01, 8/7/07-5/31/2012.
22. Co-Chairman (7.5%), FHCRC Subcontract, NIH/University of Michigan, CA037429/F0021100. Symptom Control and Quality of Life Committee, Cancer Prevention and Control Research, Southwest Oncology Group, 6/1/08-5/31/2010.
23. Principal Investigator (1 U54 CA132381), FHCRC Subcontract./Hugo Vilchis, Principal Investigator, New Mexico State University Pilot Study/U54 Pilot Study Funding [“Una Mano Amiga: Patient Navigator Program for Southwestern New Mexico”]/Beti Thompson, Principal Investigator (1 U54 CA132381-01U54), Partnership for the Advancement of Cancer Research: NMSU-FHCRC). 06/01/08-8/31/2011.
24. Investigator (15%), FHCRC, “The Time Distribution Method for Measuring Clinically Valid Quality of Life State”, Gary W. Donaldson, P. I., National Cancer Institute. R21 CA131651-01A2, 6/1/09-5/31/2011.
25. Principal Investigator (15.5%), FHCRC Subcontract, Co-Principal Investigator with Arnold Potosky, Georgetown University “Validation of PROMIS in Diverse Cancer Populations”, National Institutes of Health/National Institute of Arthritis, Musculoskeletal, and Skin Diseases, 1 U01 AR057971-01, 9/1/09-8/31/2013.
26. Investigator (5%), “Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN)”, Scott Ramsey, PI, National Cancer Institute, RC2 CA148570, 10/1/09-9/30/2011

Non-Grant External Funding:

1. GlaxoWellcome and Bristol Myers Squibb funding to support a quality of life and cost study to an ongoing Southwest Oncology Group advanced non-small cell lung cancer trial (S9505)
2. Office of Research on Minority Health award through NCI to fund minority recruitment and adherence activities, Prostate Cancer Prevention Trial (PCPT).
3. NCI end-of-year funds for PCPT Adherence Coordinator and Small Grants for PCPT sites.
4. NCI and Merck Pharmaceutical Co. funding for two videos to support PCPT adherence activities.
5. The Hope Foundation. Funding for S9916 Analgesic Use Data Extraction & Entry Pilot Project: SWOG-9916.
6. Principal Investigator (10%), FHCRC subcontract, Cancer Therapy and Research Foundation, SWOG9916 Quality of Life Data, 8/21/06-6/30/09.

Professional Memberships:

International Society for Quality of Life Research.

Southwest Oncology Group.

Professional Activities:

International:

International Society for Quality of Life Research:

Co-Chair, Scientific Program Committee, 2000 Meetings, Vancouver, B.C.; Co-Chair, Workshops

Member, Scientific Program Committee, 2001 – 2008 Annual Meetings

Chair, Workshop Subcommittee of Education Committee (11/02 to 12/31/06)

Elected Member of ISOQOL Board of Directors, 10/06 – 10/09

President-Elect of ISOQOL, 2010

National:

Statistical Center Liaison: Quality of Life and Behavioral and Health Outcomes Subcommittees of the Cancer Control Research Committee/Southwest Oncology Group, 1988-present.

Cancer Control Research Committee/Southwest Oncology Group, 1988-present.

Committee on Women's Health/Southwest Oncology Group, 1992-present.

Quality of Life Committee (Chair), SWOG Prostate Cancer Prevention Trial, 1993-present.

Quality of Life Committee (Co-Chair), SELEnium and vitamin E Cancer Prevention Trial (SELECT), 1999-2002.

Recruitment and Adherence Committee, SWOG Prostate Cancer Prevention Trial, 1993-present.

Recruitment and Adherence Committee, SELEnium and vitamin E Cancer Prevention Trial (SELECT), 1999-2002.

Quality of Life Committee, (NSABP) 1992-2002.

American Society of Clinical Oncology/National Cancer Institute Planning Committee/Working Group on Economic Analyses in Phase III Clinical Trials, 1995-1998.

World Health Organization Quality of Life Group/Cancer Module Working Group, 1993-1996.

Member of the Program Planning Committee/Chair, Methodology Subgroup, Psychosocial Interventions in Breast Cancer Workshop. American Cancer Society, November, 1998.

Participant, National Clinical Trials and Asian American Women Summit, October, 1998. Sponsored by the National Asian Women's Health Organization, the Office of Special Populations/National Cancer Institute, and the Office of Research on Women's Health/National Institutes of Health.

Quality of Life Assessment/Pharmaceutical Industry Consulting: Burroughs Wellcome Co.; RIBI Immunochem, Inc.; Dupont-Merck Oncology Division; Axion; Amgen; Rhône-Poulenc Rorer; Eli Lilly.

Member, Quality of Life Subcommittee, Oncologic Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, 10/99–11/00 (committee disbanded).

Participant, Consensus Meeting on Assessing Clinical Significance for Oncology QOL Assessment, Mayo Clinic, October 6-7, 2000, Rochester, MN. Member, Planning Committee, Follow-up Meeting, April 2002. Member, Clinical Significance Consensus Meeting Group, 2000-present.

Member, Cancer Outcomes Measurement Working Group, Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, December, 2000-present.

Member, Intergroup Quality of Life Committee, Cancer Treatment and Evaluation Program, Division of Cancer Treatment, National Cancer Institute, March, 2001-present.

Behavioral Science Member, Kidney/Bladder Cancer Progress Review Group (PRG), National Cancer Institute, July, 2001-2002.

Member, Oncology Outcomes Advisory Board, AstraZeneca, April 2002-present.

Member, IRESSA Symptoms Advisory Board, AstraZeneca, March 2003-present.

Member, Quality of Life Science Advisory Committee, American Cancer Society, March 2003-present.

Chair, Quality of Life Science Advisory Committee, American Cancer Society, January 2006 to December, 2006.

External Advisory Board: MD Anderson Community Clinical Oncology Program Research Base, March 2006.

Faculty Member, AACR/ASCO Workshop. Methods in Clinical Cancer Research. August 17-23, 1996 (Park City, Utah) and July 22-28, 2006 (Vail, Colorado).

Member, National Cancer Institute Symptom Management and Quality of Life Steering Committee, March 2007 to present.

Co-Chair, Southwest Oncology Group Symptom Control and Quality of Life Committee, January 2008 - present.

Internal:

1. Fred Hutchinson Cancer Research Center Institutional Review Board, Committee A, 1995-1997.
2. Advisory Committee Member, National Cancer Institute Training Grant on Health Behavior and Health Outcomes (D. Patrick, PhD, P.I.) proposal submitted October, 2000.
3. Donald Patrick, Carol Moinpour, HSERV 584/Pharm 535: Assessing Outcomes in Health and Medicine. Winter quarter 2002 (Wednesdays 9:00 - 11:00 am).
4. Program Advisory Committee, Long-Term Follow-Up Program Project Application, Paul Martin, Principal Investigator, Submitted 7/1/02, National Cancer Institute
5. Advisory Board Member, FHCRC Survivorship Center, Lance Armstrong Foundation Network of Survivorship Center, January 1, 2006-December 31, 2010.

Reviewer:

External Referee: Research Grant Application to the National Institute of Canada, December, 1991.

External Referee: Research Grant Application to the National Institute of Canada, December, 1993.

Member of a Special Emphasis Panel/Social Science and Population Study Section, National Institutes of Health, August 17, 1992.

Member of Agency for Health Care Policy and Research Special Study Section to Review Applications for the PORT II RFA, March 2-4, 1994.

Reviewer for the Cancer Research Campaign/Department of Health Joint Programme on Black & Minority Ethnic Groups and Cancer, October/November, 1998.

Member, Review Committee, Survivorship Research Grants, Lance Armstrong Foundation.

Member, Special Review Panel, RFA CA-05-013, "Reducing Barriers to Symptom Management and Palliative Care", February 15, 16, 2005.

Manuscript Review: Annals of Behavioral Medicine; Blood; The British Journal of Medical Psychology; CA-A Cancer Journal for Clinicians; Cancer; Controlled Clinical Trials; Critical Reviews in Oncology; Journal of Clinical Oncology; Journal of Clinical Epidemiology; Journal of Palliative Care; Journal of the National Cancer Institute; Medical Care; Oncology; Psychosomatic Medicine; Quality of Life Research; The Lancet.

Editorship Responsibilities:

Associate Editor, Quality of Life Research, July 2004 – June 2009.